Johnson Matthey Catalysis and Chiral Technologies Introduces Catalytic Reaction Guide Mobile Application
Johnson Matthey Catalysis and Chiral Technologies (JMCCT), a business unit of Johnson Matthey Fine Chemical Division, has announced the launch of its Catalytic Reaction Guide (CRG) as a free mobile application. The app has been introduced to provide customers mobile access to catalyst recommendations on more than 150 chemical reactions in the area of homogeneous, heterogeneous and asymmetric catalysis. Users can easily view and search a full product listing with streamlined technical support, take advantage of an efficient quotation request process, and obtain contact information for a complete services offering.
As the only app of its kind on the market, JMCCT was motivated to make the guide mobile to enable informed purchasing decisions anywhere in the world. In addition to catalyst recommendations, the app features a convenient Chemical Abstracts Service searchable product listing and relevant literature references. The interface is fully customizable through a user profile that synchronizes data with other devices for easy tracking of recommendations and details.
“JMCCT strives to stay at the forefront of technology, not only in the products we offer, but in how we communicate with our customers. The CRG app is a cutting-edge, efficient means for customers to access catalytic reaction data, and tap into JMCCT’s technical knowledge on the go,” said Gerard Compagnoni, General Manager of Johnson Matthey Catalysis and Chiral Technologies. “We are very excited to introduce the app for the benefit of our customers, and are looking forward to shortly debuting the online version of the CRG to round out this resource.”
The migration to a digital platform was directly driven by customer demand for the CRG in a more manageable format than traditional print, and was formally completed and put into beta testing in late 2014. Customers may download the app for free on any iPhone, iPad or Android device. A complementary online CRG will go live on the JMCCT website in spring 2015.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.